Healthcare Myths Dominate Mid-term Elections

 

Healthcare is a major issue in the mid-term elections. That’s understandable since ObamaCare has been such a disaster. What’s not understandable is Democratic claims that voters should trust them to fix the problem they created in the first place!

In my home state of Florida, Democratic Senator Bill Nelson is running ads where he attacks his Republican opponent, Governor Rick Scott, on his healthcare record. He falsely claims Scott and the Republicans want to do away with pre-existing conditions protections. Then he accuses Scott of blocking Medicaid expansion in Florida – as if expanding Medicaid would be a good thing!

ObamaCare tried to force every state into expanding Medicaid for healthy childless adult males who earn up to 138% of the poverty limit. The Supreme Court struck down this provision, allowing states to make their own determinations.

Blue states jumped on board this government give-away train when ObamaCare promised 100% federal coverage of the cost for three years, tapering off to 90% at present. More than 30 states voted to expand Medicaid under these rules.

How has this worked out for those who expanded Medicaid?

There’s no such thing as a “free lunch.” That’s the first lesson you learn when you become an adult. Those states who expanded their Medicaid are learning this lesson the hard way.

The Wall Street Journal editorial board says, “Every state that has expanded Medicaid has blown the budget by spending more money on more people. The cost overruns are more than double on average.”

On November 6, four states will consider ballot initiatives on expanding Medicaid: Nebraska, Utah, Idaho and Montana, the last of which would extend an expansion that is set to expire. Montana’s expansion has come in 70% over budget, according to the Foundation for Government Accountability. The state is now proposing to fund its expansion with a tobacco tax, which is impressive cynicism even for politicians.

Utah is proposing to raise the sales tax to 4.85% from 4.7% – a regressive tax on the poor to pay for health care for those above the poverty line. Nebraska and Idaho’s ballot measures leave the funding details for another day, ostensibly because voters might figure out that expansion is more expensive than it appears.

Oregon proposed new taxes this year to fund the cost of Medicaid expansion and Medicaid is already the fastest growing line item in nearly every state in the country. The incentive in all of these states will be to cut services from the needy, who receive traditional Medicaid, because it saves states more money.

Unlike the federal government, states must balance their budgets. That means spending more money to pay for Medicaid means less to pay for other important budget items like education, law enforcement and roads. In Idaho the compound annual growth rate for Medicaid spending over the past decade or so triples that of schools and roads, as the Idaho Freedom Foundation points out. And that’s before expansion. So, that “free money” wasn’t so free!

What about accepting the expense “for compassion’s sake?”

First, these newly enrolled patients are not pregnant women, children or the disabled, who are covered by other government healthcare programs. These are able-bodied adult males – many who refuse to work even though jobs are now plentiful. Medicaid was never intended for this demographic profile from its inception.

Second, Medicaid is the worst form of healthcare insurance – arguably worse than having no insurance at all. The Oregon Healthcare Experiment, begun in 2007, has shown those patients on Medicaid are no better off than those patients with no insurance at all when measuring common healthcare data such as blood sugar and blood pressure control.

These Medicaid patients also use emergency rooms for primary care 40% more than the uninsured. Patients without insurance actually have greater access to healthcare  since they can negotiate cash payments to doctors, which is illegal for Medicaid patients. Studies on Medicaid patients repeatedly show poorer healthcare outcomes than any other form of healthcare insurance.

Here’s how the WSJ summarizes Medicaid expansion: “Medicaid expansion is a bad fiscal and healthcare bargain that looks worse as time passes. States like Kentucky are already looking for reforms like work requirements before the “free” money drowns their state fisc. Voters would be wise to reject the phony compassion and focus scarce resources on the poor and disabled.”

I’m thankful that Governor Scott resisted the pressure to expand Medicaid in the State of Florida – and all Floridians should be thankful, too. Senator Nelson was a part of the problem that created our healthcare mess and he won’t be part of the solution to fix it.

Trump’s Radical Plan to Lower Medicare Drug Prices

 

President Trump is thinking outside the box. He has just proposed a radical new plan intended to lower Medicare drug prices.

Avik Roy, writing in Forbes, describes the Trump administration plan just revealed to substantially reduce the price of certain costly drugs administered under Medicare, by linking what Medicare pays for these drugs to what other industrialized countries pay. Roy calls this “a stunning move that could entirely reshape the way the pharmaceutical and biotechnology industries think about their business model.”

It is no secret that Americans pay more for their drugs than do other countries. This has always been sold to the American people as a “necessary evil” so that pharmaceutical companies can develop new drugs. Here is what President Trump said in remarks made to the press:

“For decades, other countries have rigged the system so that American patients are charged much more – and in some cases, much, much more – for the exact same drug. In other words, Americans pay more, so that other countries pay less.”

 

Roy explains how we got to this point. Beginning in the 1990s, the pharmaceutical industry poured most of its resources into developing “blockbuster” drugs that addressed large public health problems, like high blood pressure and high cholesterol. Most famously, Pfizer developed Lipitor, a cholesterol-lowering drug that went on to become the best-selling drug of all time with global revenues exceeding $20 billion per year before its patent expired.

However, in the 2000s, a new strategy evolved where pharmaceutical giants like Roche, a Swiss company, and its U.S. subsidiary, Genentech, focused on so-called “orphan” or rare diseases. These diseases affected fewer than 250,000 Americans, but less competition and lower R&D expenditures made them more lucrative. The clinical trials phase of development was cheaper and shorter and higher prices with lower costs made for higher profits.

Fuel for Higher Medicare Part B Drug Prices

Medicare Part B for seniors covers drugs administered in a doctor’s office, such as those requiring an intravenous infusion. Once the drug is approved by the FDA, the drug company can charge whatever they want and Medicare pays for it. This is not a market-driven price but rather a private industry price control.

Roy explains how drug companies benefit: “This quirk in U.S. policy has fueled development of drugs that hit the sweet spot of Medicare Part B: drugs that are administered in a doctors’ office (not those you buy at your pharmacy), and drugs that treat diseases of old age (because Medicare is for people over 65). That sweet spot coincides with where we are increasingly spending more on prescription drugs: cancer, inflammatory arthritis, and the like.”

In addition, the Medicare Modernization Act of 2003 awarded doctors a 6% commission on drug infusions that is tied to the average selling price of a drug. This incentivizes physicians to steer patients to costlier drugs, because the physician gets a higher commission.

The Trump Proposal

The Trump proposal addresses the problems of Medicare Part B in two ways:

  • Eliminate the 6% doctor commission – replace it with a fixed fee. This removes the incentive to steer patients to more expensive drugs.
  • Link Medicare Part B prices to an International Pricing Index – This will be based on sixteen countries chosen because they found it relatively easy to acquire pricing data from these countries.

 

The program would be piloted under the Center for Medicare & Medicaid Innovation, an agency created by the Affordable Care Act to investigate ways to make the Medicare and Medicaid programs more cost-effective. The pilot would cover half of the U.S. population, and the administration estimates that the plan could reduce Medicare Part B spending by $17 Billion over the next five years.

The savings is not just for the government. Since seniors on Medicare are required to pay for a share of their Medicare Part B drug costs, lower Medicare drug prices would translate into significant savings for seniors receiving infused medications.

Of course, the pharmaceutical industry will fight back. Look for them to spread fear that this will eliminate new research for improved medicines. But be thankful that Trump is willing to take on this fight. His predecessors certainly never did.

Fake Drugs Can Be Fatal

 

“Fake News” can be misleading. “Fake Drugs” can be fatal.

That’s the take-home message of Carrie Luther, mother of Tosh Ackerman, who died after taking a fake Xanax pill filled with Fentanyl. Fentanyl is a synthetic opioid that is approximately 100 times stronger than morphine. It is highly addictive and very dangerous since it can cause respiratory arrest. It is frequently added to counterfeit drugs because it is inexpensive to manufacture and leads to addiction – thereby encouraging more use of the counterfeit drug.

Fentanyl is so dangerous that it is only permitted to be used in hospitals in locations where monitoring of respirations and emergency resuscitation equipment is readily available – like the emergency room or operating room. I know from a personal kidney stone experience that I could receive Fentanyl in the E.R. when I came in but I couldn’t receive it on the hospital floor after I was admitted.

According to Sumathi Reddy, writing in The Wall Street Journal, the problem is online sales of pharmaceuticals. Reddy says the issue of counterfeit prescription medications like Xanax is a growing problem, attracting the attention of law enforcement organizations and pharmaceutical companies like Pfizer, which manufactures Xanax.

In June the U.S. Food and Drug Administration convened a meeting around the problem of illegal opioids sold online and through social media. “Millenials and those younger rely heavily on social media, “ says Alex Khu, assistant director of the U.S. Immigration and Customs Enforcement’s Global Trade Investigations division. “Criminal organizations recognize that trend and we’re starting to see advertisement and sales of counterfeit or substandard prescription drugs on social media sites.”

“The biggest danger is that these sites do not require a medical examination or a prescription, and the sites do not impose limitations on how much or how often the consumer purchases drugs,” Khu says.

The National Association of Boards of Pharmacy reviewed nearly 12,000 internet drug outlets selling prescription medications to U.S. patients. Of these, about 95% were found noncompliant with state and federal laws and NABP standards, according to a report published in September, which highlights the role social media sites play.

Pfizer manufactures Xanax, an antianxiety drug also known as alprazolam. Since its patent has expired other companies are free to make and sell the same drug in generic form. Over the past three years Pfizer has reported more than 10,000 Facebook accounts or profiles selling counterfeit Pfizer medications to the social media company. They’ve also referred more than 1,000 Instagram accounts selling counterfeit Pfizer products over the past six months to Facebook, the parent company of Instagram.

Counterfeit Xanax and other drugs are indistinguishable to the naked eye from the real thing. Only with magnification and training can one distinguish the difference.

How big is this problem?

Thomas Kubic, president and CEO of the Pharmaceutical Security Institute, a Virginia –based nonprofit, says there are roughly 15,000 to 17,000 annual cases of counterfeit drugs reported globally to his organization from its members, who include security directors from 33 pharmaceutical companies. Obviously this represents only the tip of the iceberg.